Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Rain Oncology

Evaluate

Thumbnail
June 07, 2022

Asco 2022 – PMV’s therapeutic window slams shut

Liver and other toxicities threaten to scupper another attempt to reactivate mutated p53, the “guardian of the genome”.

Thumbnail
November 30, 2021

Blueprint takes a long shot at a small niche

Article image
Vantage logo
May 24, 2021

J&J’s bispecific wins first approval for exon 20 lung cancer niche

Article image
Vantage logo
May 20, 2021

Asco 2021 – Merus intrigues in pancreatic cancer

Article image
Vantage logo
February 01, 2021

World Lung 2020 – amivantamab puts more data behind the hype

But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?

Article image
Vantage logo
July 28, 2020

A turn-up for Spectrum’s book

Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.

Article image
Vantage logo
November 28, 2019

The first test of Spectrum’s shift

By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.

Article image
Vantage logo
August 28, 2019

World Lung preview – Astra takes on Roche

Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.

Article image
Vantage logo
June 04, 2019

Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche

cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up